MatBA® for Follicular Lymphoma
Follicular lymphoma (FL) accounts for about 22% of all non-Hodgkins lymphoma cases. Approximately 15,500 new cases of FL are diagnosed each year in the U.S. FL is characterized by typical morphology and the presence of chromosomal translocation t(14;18)(q32;q21). Although FL typically has a slow progression over time (the median survival time is over 10 years), accurate information about prognosis is highly desirable in order to determine the best course of treatment.
While low stage FL patients are often put under watch-and-wait surveillance, a significant portion of follicular lymphoma cases are not discovered until they are at advanced stages. These cases often require treatment, most often immunochemotherapy. Over time, up to 45% of FL undergoes transformation into an aggressive form of lymphoma, usually diffuse large B-cell lymphoma (DLBCL) which is associated with poorer outcomes. Biomarkers can help determine whether a follicular lymphoma is likely to undergo such a change, and therefore are helpful to patient management.
In order to assist clinicians in the prognosis of FL, CGI has developed the mature B-cell neoplasm array, also known as MatBA®-FL. This assay is based on the detection of targeted gain/loss of genomic material with prognostic value frequently observed in FL. Test results are reported out in a format that allows for ease of interpretation, guiding the clinical management of FL.
MatBA®-FL Array-CGH identifies information on fourteen distinct chromosomal regions, providing valuable prognostic data and critical information about the risk of progression of the disease.
|Reported Loci||Genomic Aberration|
|6q (6q12-q16.3 and TNFAIP3)||Loss|